Drug Profile
MMR-varicella zoster virus vaccine - GlaxoSmithKline
Alternative Names: GSK-208136; MMRVNS; Priorix-Tetra; PriorixTetraLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Measles vaccines; Mumps vaccines; Rubella vaccines; Varicella vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Measles; Mumps; Rubella; Varicella zoster virus infections
Most Recent Events
- 06 Oct 2016 No development reported - Phase-III for Measles (Prevention) in South Korea (SC)
- 06 Oct 2016 No development reported - Phase-III for Mumps (Prevention) in South Korea (SC)
- 06 Oct 2016 No development reported - Phase-III for Rubella (Prevention) in South Korea (SC)